1 week ago
Symbiotec Pharmalabs IPO Opens With 42% Grey-Market Premium
Symbiotec Pharmalabs has started selling shares to the public through an IPO.
People can bid for the shares until 26 August 2026.
Each share is priced between ₹938 and ₹988.
Investors must apply for at least one group of 15 shares.
The company hopes to raise ₹1,757 crore through new shares and shares sold by existing holders.
In the grey market, the shares are reportedly trading ₹411 above the top IPO price.
This suggests a possible strong listing, but grey-market prices are not guaranteed.
One analyst has recommended applying for the IPO for the long term.
Symbiotec Pharmalabs’ IPO opened for bidding and will remain open until 26 August 2026.
The price band is ₹938–₹988 per equity share, with a lot size of 15 shares.
The issue is reported at ₹1,757 crore, comprising ₹150 crore in fresh shares and ₹1,607 crore through an offer for sale.
The grey-market premium is ₹411, implying an indicated listing gain of about 42% over the upper price band.
KC Securities’ Mahesh M Ojha assigned the issue an “apply” recommendation for long-term investors, citing exports, regulatory approvals and valuation.
- Who
- Symbiotec Pharmalabs Ltd and investors bidding for its IPO.
- What
- A ₹1,757 crore IPO comprising a fresh issue and an offer for sale.
- Where
- The shares are proposed to be listed on the BSE and NSE.
- When
- The issue is open until 26 August 2026; allotment is tentatively scheduled for 27 August and listing for 1 September 2026.
- Why
- The company is raising funds through fresh shares while also offering shares through the OFS route.
Key facts
- Price band
- ₹938–₹988 per equity share
- Issue size
- Reported as ₹1,757 crore: ₹150 crore fresh issue and ₹1,607 crore OFS
- Grey-market premium
- ₹411 per share, indicating an approximately 42% premium over the upper price band
- Lot size
- 15 shares
- IPO window
- Open through 26 August 2026, from 10:00 AM to 5:00 PM on trading days
- Tentative dates
- Allotment on 27 August 2026 and listing on 1 September 2026
- Registrar
- MUFG Intime India Private Limited
- Reported inconsistencies
- The article also writes the issue size as ₹1.757 crore and contains references to Skyways Air Services IPO and Behari Lal Engineering, which do not match the Symbiotec Pharmalabs details.
Quotes
Mahesh M Ojha
Vice President for Research and Business Development at KC Securities
“Symbiotec Pharmalab Ltd. is an integrated, backwards-integrated pharmaceutical and biotechnology platform focused on steroidal hormone and corticosteroid APIs, nutritional ingredients and speciality products, serving over 40 countries.”
livemint.com
“At 58.36x post-IPO FY26 P/E, the valuation appears relatively attractive versus listed peers. Hence, we recommend Investors to subscribe for a long-term horizon.”
livemint.com
Sources
Related news
Symbiotec Pharmalab Shares Set for Premium Market Debut
Symbiotec Pharmalab IPO Opens With ₹1,757 Crore Offer
Symbiotec Pharmalab IPO Draws Strong, Conflicting Subscription Figures
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
Symbiotec Pharmalab IPO Opens With Analysts Recommending Subscription
ESDS Software Solution IPO Allotment, GMP Signals Listing Gains
Priority Jewels IPO Draws Strong Demand Despite Valuation Concerns
Augmont Enterprises Shares Debut 22% Higher, Extend Gains
ESDS Software Solution IPO Shows Strong Demand, Analysts Say Apply
Priority Jewels IPO Fully Booked on Strong Retail Demand
